NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
AstraZeneca Pharma India Shareholders Approve Material Related Party Transactions
AstraZeneca Pharma India Limited has announced that its shareholders have approved ordinary resolutions regarding material transactions with related parties via a postal ballot. The voting results, declared on March 31, 2026, confirm that the resolutions were passed by non-related members with the requisite majority. This approval is a mandatory regulatory requirement under SEBI (LODR) Regulations for significant business dealings with group entities. The successful vote ensures the company remains compliant while executing its operational strategy involving parent or sister concerns.
முக்கிய அம்சங்கள்
Ordinary resolutions for Material Related Party Transactions passed with requisite majority.Voting results finalized on March 31, 2026, following a Postal Ballot notice dated February 11, 2026.Approval obtained specifically from non-related members to ensure fair corporate governance.Compliance maintained under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
No immediate action is required as this is a routine regulatory approval for business operations. Investors should monitor future financial statements to understand the scale and impact of these related party transactions on margins.
AstraZeneca India Receives CDSCO Approval for Imfinzi to Treat Liver Cancer (uHCC)
AstraZeneca Pharma India has received approval from the CDSCO to import and market Durvalumab (Imfinzi) for an additional indication in India. The drug is now indicated for treating unresectable hepatocellular carcinoma (uHCC) in patients who have not received prior systemic therapy. This approval covers two dosage strengths: 120 mg/2.4 mL and 500 mg/10 mL. This expansion into liver cancer treatment strengthens the company's oncology portfolio and opens a new revenue stream in the Indian market.
முக்கிய அம்சங்கள்
Received CDSCO permission for import and distribution of Durvalumab (Imfinzi) for a new indicationIndicated for unresectable hepatocellular carcinoma (uHCC) in treatment-naive patientsApproval covers two formulations: 120 mg/2.4 mL and 500 mg/10 mL solution for infusionExpands AstraZeneca's oncology portfolio and addressable market in India
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for long-term growth in the oncology segment. Monitor the commercial rollout and its impact on the company's specialty care revenue in upcoming quarters.
AstraZeneca Pharma India Seeks Approval for ₹3,900 Cr Related Party Transactions
AstraZeneca Pharma India Limited has issued a postal ballot notice to seek shareholder approval for material related party transactions (RPT) for the 2026-27 fiscal year. The company proposes transactions worth up to ₹2,400 crore with AstraZeneca UK Limited and up to ₹1,500 crore with AstraZeneca AB, Sweden. These transactions cover the purchase, transfer, or receipt of products, goods, and services essential for operations. The e-voting period is scheduled from February 28 to March 29, 2026, with results expected by March 31, 2026.
முக்கிய அம்சங்கள்
Proposed transactions with AstraZeneca UK Limited capped at ₹2,400 crore for FY 2026-27.Proposed transactions with AstraZeneca AB, Sweden capped at ₹1,500 crore for FY 2026-27.Total value of material related party transactions under consideration is ₹3,900 crore.E-voting period runs from February 28, 2026, to March 29, 2026.Transactions include purchase of products, goods, materials, and reimbursement of transfer price or other obligations.
👀 கவனிக்க வேண்டியவை
Investors should monitor the voting results and review the explanatory statement to ensure these large-scale transactions with parent entities are conducted at arm's length.
AstraZeneca India Q3 Revenue Surges 39% to INR 6,115.7 Mn; 8 New Regulatory Approvals Secured
AstraZeneca Pharma India reported a robust 39% YoY growth in total revenue for Q3 FY 2025-26, reaching INR 6,115.7 Mn. The growth was primarily driven by the Oncology segment, which contributed INR 4,395.9 Mn, and Biopharmaceuticals at INR 1,377.4 Mn. The company demonstrated strong pipeline execution with 8 new regulatory approvals over the past nine months, including key indications for Durvalumab and Osimertinib. Profit after tax for the quarter stood at INR 465.4 Mn, supported by consistent performance across all therapy areas.
முக்கிய அம்சங்கள்
Total revenue for Q3 FY 2025-26 grew 39% YoY to INR 6,115.7 Mn.Oncology segment contributed INR 4,395.9 Mn, representing approximately 72% of total quarterly revenue.Secured 8 new regulatory approvals in 9 months, including treatments for endometrial cancer, MIBC, and rare diseases.9-month (Apr-Dec '25) total revenue reached INR 16,969.7 Mn with a Profit Before Tax of INR 1,982.3 Mn.Launched Eculizumab, the first anti-complement therapy in India for rare diseases aHUS and PNH.
👀 கவனிக்க வேண்டியவை
Investors should note the strong revenue momentum and the significant expansion of the product portfolio through 8 new approvals. The company's focus on high-value oncology and rare disease segments suggests a positive outlook for long-term margin improvement.
AstraZeneca India Gets CDSCO Approval for Imfinzi in Endometrial Cancer Treatment
AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import and market Durvalumab (Imfinzi) for an additional indication. The drug is now approved for first-line treatment of adults with primary advanced or recurrent endometrial cancer in combination with chemotherapy. This approval covers two dosage forms: 120 mg/2.4 mL and 500 mg/10 mL. This regulatory milestone allows the company to expand its oncology portfolio and address a critical therapeutic area in the Indian market.
முக்கிய அம்சங்கள்
Received CDSCO permission to import and distribute Durvalumab (Brand: Imfinzi) for a new indication.Approved for first-line treatment of primary advanced or recurrent endometrial cancer in combination with chemotherapy.Available in two dosage strengths: 120 mg/2.4 mL and 500 mg/10 mL solution for infusion.Includes maintenance treatment as monotherapy for mismatch repair deficient (dMMR) endometrial cancer.
👀 கவனிக்க வேண்டியவை
This is a positive development that strengthens AstraZeneca's oncology pipeline in India. Investors should monitor the impact on specialty segment revenues in future earnings reports as the product is commercialized for this new indication.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
AstraZeneca India Gets CDSCO Approval for Imfinzi to Treat Gastric Cancer
AstraZeneca Pharma India has received approval from the CDSCO to import and market Durvalumab (Imfinzi) for an additional indication in India. The drug is now permitted for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) in combination with FLOT chemotherapy. This approval covers two dosage strengths: 120 mg/2.4 mL and 500 mg/10 mL. This expansion of Imfinzi's therapeutic use is expected to enhance the company's oncology portfolio and addressable patient base.
முக்கிய அம்சங்கள்
Received CDSCO permission to import and distribute Durvalumab (Imfinzi) for a new oncology indication.Approved for treating adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).Permission covers two specific formulations: 120 mg/2.4 mL and 500 mg/10 mL solutions for infusion.The treatment protocol involves combination with FLOT chemotherapy followed by single-agent Durvalumab.The approval paves the way for immediate marketing subject to any remaining statutory requirements.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial launch and uptake of Imfinzi for this new indication as it strengthens the company's high-margin oncology segment. This regulatory milestone is a positive driver for long-term revenue growth in the Indian market.
AstraZeneca Pharma India Appoints New Directors for Oncology and Institutional Business
AstraZeneca Pharma India has announced two key senior management appointments effective January 12, 2026, to strengthen its commercial leadership. Ms. Aditi Dayarus Mehta, with over 15 years of experience from Pfizer and BMS, joins as Director of the Oncology Business Unit. Mr. Nitin Bindal, an IIT Bombay and UCLA alumnus with 17 years of experience at BMS and J&J, has been appointed as Director for Institutional Business & Public Channels. These strategic hires from top-tier global competitors are aimed at driving growth in high-value therapeutic areas and expanding market access.
முக்கிய அம்சங்கள்
Ms. Aditi Dayarus Mehta appointed as Director – Oncology Business Unit with 15+ years of leadership experience.Mr. Nitin Bindal appointed as Director - Institutional Business & Public Channels with 17+ years of industry expertise.Both appointments are effective from January 12, 2026, following Board and NRC approval.New leaders bring specialized experience from global giants including Pfizer, Bristol Myers Squibb, and Johnson & Johnson.
👀 கவனிக்க வேண்டியவை
Investors should view these high-caliber hires as a positive step toward strengthening the company's core oncology and institutional segments. Monitor the execution of new strategies in these divisions over the coming fiscal year.
AstraZeneca Pharma Receives CDSCO Approval for New Breast Cancer Drug Datverzo in India
AstraZeneca Pharma India has received permission from the CDSCO to import and market Datopotamab Deruxtecan (Brand name: Datverzo) 100 mg in India. The drug is indicated for adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have previously received endocrine-based therapy and chemotherapy. This approval strengthens the company's oncology portfolio in the Indian market. Commercial marketing will commence following the receipt of any remaining statutory approvals.
முக்கிய அம்சங்கள்
Received CDSCO approval for import and distribution of Datverzo (Datopotamab Deruxtecan) 100 mgIndicated for metastatic HR-positive, HER2-negative breast cancer in adult patientsTargets patients who have failed prior endocrine-based therapy and chemotherapyMarks a significant addition to AstraZeneca's specialty oncology pipeline in India
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial launch timeline and the drug's adoption rate in the oncology segment, as it expands the company's high-margin specialty medicine portfolio.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
